In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Biogen spins off hemophilia business; to be named Bioverativ

Executive Summary

Biogen Inc. is spinning off its hemophilia business as an independent publicly traded company. The new company hasn’t been named yet, but Biogen expects the transaction to be completed by the end of the year or early 2017.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Divestiture/Spin-Out
    • Intra-Biotech Deal

Related Companies

UsernamePublicRestriction

Register